HCA stock forecast, quote, news & analysis

Key Takeaways

• HCA Healthcare shares closed at $371.18 on July 17, 2026, reflecting a modest 1.1% decline over the trailing 30-day period from mid-June.
• The company lowered its full-year 2026 EPS guidance to $28.70–$30.50 on July 14, citing a $400 million unfavorable payer mix shift driven by rising uninsured patient volumes.
• Preliminary Q2 revenue of approximately $20.23 billion beat consensus estimates, but declining surgical volumes and exchange-coverage headwinds pressured the outlook.
• Analyst consensus remains a Moderate Buy with an average price target of $486.14, though multiple firms have trimmed targets following the guidance revision.
• The stock trades at a P/E ratio of roughly 12.8, well below its 52-week high of $556.52 reached in March 2026, and approximately 34% beneath that peak.

Current Market Snapshot

HCA Healthcare shares have traded within a relatively narrow band over the past 30 days, closing at $371.18 on July 17 compared with $375.17 on June 18, a decline of roughly 1.1%. That modest move belies significant underlying volatility: the stock experienced a sharp single-day drop of more than 7% on July 14 after management revised its full-year profit forecast downward, briefly sending shares below $365 before a partial recovery. The broader healthcare facilities sector has faced mounting headwinds from policy uncertainty, while peers such as Universal Health Services and Tenet Healthcare have also come under pressure. With a 50-day moving average of approximately $392 and a 200-day moving average near $457, the stock currently trades well below both medium- and long-term trend benchmarks.

HCA Healthcare (HCA) Business Overview and Competitive Position

HCA Healthcare, headquartered in Nashville, Tennessee, is the largest for-profit hospital operator in the United States. Founded in 1968, the company owns and operates roughly 190 acute-care hospitals and more than 2,500 outpatient facilities across 19 states and maintains a small presence in the United Kingdom. Its integrated network spans general and acute-care hospitals, freestanding surgery centers, urgent care clinics, emergency rooms, diagnostic imaging centers, and rehabilitation facilities. This scale creates meaningful competitive advantages in purchasing power, clinical staffing leverage, and reimbursement negotiations. HCA's ability to guide patients across its owned network—from urgent care entry points through acute hospital stays and into post-acute services—forms an integrated continuum that few competitors can replicate. The company serves a payer mix spanning commercial insurance, Medicare, Medicaid, and self-pay segments, making reimbursement dynamics a persistent variable in its margin calculus.

Recent Developments Driving HCA

The most consequential development for HCA in recent weeks was its July 14 preliminary second-quarter release and accompanying full-year guidance revision. While Q2 revenue of approximately $20.23 billion exceeded the consensus estimate of roughly $19.4 billion, the details revealed meaningful operational softness. Same-facility inpatient surgeries declined 2.3% and outpatient surgeries fell 3.4% year-over-year, even as emergency room visits rose 3.6% and total admissions increased 2.5%. The bigger concern centered on payer mix: HCA disclosed an estimated $400 million unfavorable impact on Q2 pretax income from an increase in uninsured and exchange-plan patients, a consequence of the expiration of enhanced Affordable Care Act premium tax credits at the end of 2025. The company now projects a full-year exchange-related drag of $1.0–$1.2 billion, up sharply from its prior $600–$900 million estimate.

As a result, management lowered 2026 EPS guidance to $28.70–$30.50 from $29.10–$31.50, trimmed adjusted EBITDA guidance to $15.4–$16.1 billion, and narrowed the revenue forecast to $77.0–$79.5 billion. On a more positive note, the company recognized approximately $400 million in incremental benefits from Medicaid Supplemental Payment Programs, primarily tied to a recently approved Florida state-directed payment initiative. Analyst reactions were mixed but largely cautious: RBC Capital lowered its price target to $435 from $534 while maintaining an Outperform rating; Barclays downgraded the stock to Equal Weight on July 8; Cantor Fitzgerald trimmed its target to $525 from $588 and retained an Overweight rating. HCA's official second-quarter earnings call is scheduled for July 24.

Trending AI Robots

For investors seeking data-driven approaches to navigate evolving markets, Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing AI trading bots. Tickeron hosts hundreds of automated trading bots that collectively trade thousands of tickers across equities, ETFs, and other asset classes, but only those demonstrating the strongest recent performance and highest relevance appear in this featured section. Each bot operates with its own defined strategy, timeframe, and risk profile, enabling users to evaluate options aligned with their specific objectives. Performance metrics, trade histories, and key statistics are displayed transparently, allowing investors to assess each bot's track record before making decisions. Visit the Trending AI Robots page to explore the current lineup of leading algorithmic trading strategies.

2026 Outlook and What Investors Should Watch

Several interconnected factors will shape HCA's trajectory through the remainder of 2026. The most immediate catalyst is the July 24 earnings call, where management is expected to provide deeper detail on second-half volume trends, the pace of exchange-coverage erosion, and the durability of Medicaid supplemental payment benefits. Investors should closely monitor same-facility surgical volume data in upcoming quarters, as the 2.3%–3.4% declines reported in Q2 could signal a broader consumer pullback in discretionary medical spending. On the policy front, the expiration of enhanced ACA subsidies represents a structural shift that may continue to pressure payer mix well into 2027, and any further legislative or regulatory changes around Medicaid funding, state-directed payments, or Medicare reimbursement rates could meaningfully alter the earnings outlook. Capital allocation remains another area of focus: HCA maintained its $5.0–$5.5 billion capital expenditure plan despite the guidance cut, signaling confidence in long-term network investment. With institutional ownership at roughly 63% and a forward P/E near 12.4, valuation appears to already embed considerable caution, but execution against revised targets will be critical for restoring investor confidence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations